{"id":586154,"date":"2025-11-17T00:00:00","date_gmt":"2025-11-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including\/"},"modified":"2026-07-26T11:13:58","modified_gmt":"2026-07-26T11:13:58","slug":"algoim0056-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Constipation (including IBS without Diarrhea) | US | 2025"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers constipation-predominant IBS (IBS-C) and IBS without diarrhea. Limited treatment options are available, and only a few drugs have FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan\u2019s Linzess and Synergy Pharmaceutical\u2019s Trulance), bicyclic fatty acids (Takeda\u2019s Amitiza and Par\u2019s generic lubiprostone), and sodium\/hydrogen exchanger 3 (NHE3) inhibitors (Ardelyx\u2019s Ibsrela). These treatments are only moderately effective. Zelnorm, a 5-HT4 receptor agonist, was relaunched in 2019 for IBS-C in women younger than age 65 but was removed from the market again in 2022 for business-related reasons.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-C (including IBS without diarrhea) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C (including IBS without diarrhea) patients?<\/li>\n<li>How has Linzess been integrated into the treatment algorithm, and what is its source of business? Do Linzess, Trulance, and the newly launched generic lubiprostone continue to gain patient share?<\/li>\n<li>What percentage of IBS-C patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of IBS-C patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong><strong>Markets covered:<\/strong> United States<\/strong><\/p>\n<p><strong>Real-world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered:<\/strong> Ibsrela, Linzess, Trulance, Amitiza, lubiprostone (generic), SSRIs, SNRIs, tricyclic agents , Anticholinergics<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul>\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-586154","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}